Literature DB >> 12623361

Radiotherapy alone in the curative treatment of rectal carcinoma.

Jean-Pierre Gerard1, Pascale Romestaing, Olivier Chapet.   

Abstract

Surgery is the standard treatment for rectal adenocarcinoma. The tumour is resistant to radiation; doses above 80 Gy are necessary and have to be delivered by endocavitary irradiation. Contact radiotherapy is a basic method of delivering a high dose in a small volume. Brachytherapy can be used to deliver a boost of radiation into a residual lesion. External-beam radiotherapy can be used to supplement the dose to the deep part of the primary tumour and to the perirectal lymph nodes. T1N0 tumours have been treated by contact radiotherapy, and local control was achieved in 85-90% of patients with no severe toxic effects. Combined endocavitary irradiation and external-beam irradiation can achieve local control in 80% of patients with T2 tumours and 60% of patients with T3 tumours with only moderate toxic effects and a 60% 5-year overall survival. Radiotherapy alone is suitable for patients with T1N0 lesions (contact radiotherapy) or patients with T2-3 (combined endocavitary and external-beam radiotherapy) who cannot undergo surgery. For T2 or early T3 tumours of the lower rectum requiring surgery and a permanent colostomy, combined irradiation can be used as a first-line treatment in an attempt to avoid abdominoperineal amputation.

Entities:  

Mesh:

Year:  2003        PMID: 12623361     DOI: 10.1016/s1470-2045(03)01020-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  11 in total

1.  A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration.

Authors:  R E Horch; W Hohenberger; A Eweida; U Kneser; K Weber; A Arkudas; S Merkel; J Göhl; J P Beier
Journal:  Int J Colorectal Dis       Date:  2014-04-22       Impact factor: 2.571

Review 2.  Toward the non-surgical management of locally advanced rectal cancer.

Authors:  Alice Dewdney; David Cunningham
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  Pelvic exenteration for advanced and recurrent malignancy.

Authors:  Evita Zoucas; Sven Frederiksen; Marie-Louise Lydrup; Wiking Månsson; Pelle Gustafson; Per Alberius
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

4.  Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.

Authors:  Nicolae Bacalbasa; Adina Croitoru; Irina Balescu; Mihaela Vilcu; Adrian Neacsu; Simona Dima; Iulian Brezean
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  Progress in rectal cancer treatment.

Authors:  Wim P Ceelen
Journal:  ISRN Gastroenterol       Date:  2012-08-30

6.  Bromodeoxyuridine labeling index as an indicator of early tumor response to preoperative radiotherapy in patients with rectal cancer.

Authors:  Anna Gasinska; Jan Skolyszewski; Tadeusz Popiela; Piotr Richter; Zbigniew Darasz; Krystyna Nowak; Joanna Niemiec; Beata Biesaga; Agnieszka Adamczyk; Krzysztof Bucki; Krzysztof Malecki; Marian Reinfuss; Teresa Kowalska
Journal:  J Gastrointest Surg       Date:  2007-04       Impact factor: 3.452

7.  Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment.

Authors:  Monique Maas; Doenja M J Lambregts; Patty J Nelemans; Luc A Heijnen; Milou H Martens; Jeroen W A Leijtens; Meindert Sosef; Karel W E Hulsewé; Christiaan Hoff; Stephanie O Breukink; Laurents Stassen; Regina G H Beets-Tan; Geerard L Beets
Journal:  Ann Surg Oncol       Date:  2015-07-22       Impact factor: 5.344

Review 8.  Response Assessment with MRI after Chemoradiotherapy in Rectal Cancer: Current Evidences.

Authors:  Nieun Seo; Honsoul Kim; Min Soo Cho; Joon Seok Lim
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

9.  The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine.

Authors:  Yanli Xiong; Li Shao; Jia Liu; Qian Zhou; Chongyi Li; Maojun Liao; Lei Zhang; Xiaoyan Dai; Mengxia Li; Xin Lei
Journal:  Front Oncol       Date:  2021-11-18       Impact factor: 6.244

Review 10.  Plastic and Reconstructive Surgery in the Treatment of Oncological Perineal and Genital Defects.

Authors:  Rebekka Brodbeck; Raymund E Horch; Andreas Arkudas; Justus P Beier
Journal:  Front Oncol       Date:  2015-10-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.